Preclinical evidence supports this approach: co-targeting PYK2 and VEGFR (sunitinib) demonstrated superior anti-angiogenic and anti-invasive effects compared to monotherapy in a hepatocellular carcinoma xenograft model, suggesting synergy in disrupting PYK2-driven tumor microenvironment remodeling and survival signaling (96). Here, PTK2B is linked to hepatocellular carcinoma.